Hormone receptor positive breast cancer has both estrogen receptor positive (ER+) and progesterone receptor positive (PR+) tumor receptor status. Compounds that regulate ER or PR expression, oppose the production of estrogen in the body (i.e., oppose aromatase) or inhibit estrogen binding to estrogen receptors are among those used to treat this type of breast cancer. Hormone receptor positive tumors tend to metastasize first to the bone.

Breast cancer patients with ER+/PR+ tumors have the most favorable prognosis compared to the other estrogen/progesterone subtypes (ER+/PR-, ER-/PR+, ER-/PR-). Because this is the most hormonally driven subtype, hormone receptor positive breast cancer survivors have the greatest opportunity to influence their prognosis through diet, exercise and other lifestyle choices that can influence estrogen and other hormone levels.

Specific statistics concerning survival, which varies depending on numerous factors, can be found in the studies below. Please also see our articles on hormone receptor positive breast cancer and what to eat if you have hormone receptor positive breast cancer.